DDInter946 DDInter1376
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Interferon alfacon-1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Interferon alfacon-1 {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Interferon alfacon-1 {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Interferon alfacon-1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Baricitinib
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Aldesleukin